Skip to main content
SpringerLink
Log in

Human Papillomaviruses

  • Chapter
  • First Online:
Book cover Vaccines: A Biography

Abstract

Cervical cancer is one of the few human cancers entirely attributable to infection with a virus, human papillomavirus (HPV). It is one of the commonest cancers among women worldwide, responsible for over 250,000 deaths each year. Although chronic disease of the uterus was known in ancient times, the concept of cancer as a disorder of cell growth is relatively recent and was only confirmed with the advent of technologies for the microscopic examination of human tissue in the first half of the nineteenth century, as systematized by Virchow and others (Bracegirdle 1977).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Alphs HH, Gambhira R, Karanam B et al (2008) Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci USA 105(15):5850–5855

    Article  CAS  PubMed  Google Scholar 

  • Ault KA (2007) Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369(9576):1861–1868

    Article  PubMed  CAS  Google Scholar 

  • Ault KA, Giuliano AR, Edwards RP et al (2004) A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine 22(23–24):3004–3007

    Article  CAS  PubMed  Google Scholar 

  • Barbara A Slade, Laura Leidel, Claudia Vellozzi, Emily Jane Woo, Wei Hua, Andrea Sutherland, Hector S Izurieta, Robert Ball, Nancy Miller, M Miles Braun, Lauri E Markowitz John Iskander Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine JAMA. 2009;302(7):750–757

    Google Scholar 

  • Bell JA, Sundberg JP, Ghim S et al (1994) A formalin-inactivated vaccine protects against mucosal papillomavirus infection: a canine model. Pathobiology 62:194–198

    Article  CAS  PubMed  Google Scholar 

  • Bosch FX, de Sanjosé S (2003) Chapter 1: human papillomavirus and cervical cancer - burden and assessment of causality. J Natl Cancer Inst Monogr (31):3–13

    PubMed  Google Scholar 

  • Bosch FX, de Sanjosé S (2007) The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers 23(4):213–227

    PubMed  Google Scholar 

  • Boshart M, Gissmann L, Ikenberg H et al (1984) A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J 3(5):1151–1157

    CAS  PubMed  Google Scholar 

  • Boxman ILA, Berkhout RJM, Mulder LHC et al (1997) Detection of human papillomavirus DNA in plucked hairs from renal transplant recipients and healthy volunteers. J Invest Dermatol 108(5):712–715

    Article  CAS  PubMed  Google Scholar 

  • Bracegirdle B (1977) The history of histology: a brief survey of sources. Hist Sci 15:77–101

    Google Scholar 

  • Brown DR, Fife KH, Wheeler CM et al (2004) Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine 22(21–22):2936–2942

    Article  CAS  PubMed  Google Scholar 

  • Campo MS, Moar MH, Sartirana ML et al (1985) The presence of bovine papillomavirus type 4 DNA is not required for the progression to, or the maintenance of, the malignant state in cancers of the alimentary canal in cattle. EMBO J 4:1819–1825

    CAS  PubMed  Google Scholar 

  • Chan SY, Delius H, Halpern AL et al (1995) Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy. J Virol 69(5):3074–3083

    CAS  PubMed  Google Scholar 

  • Christensen ND, Kirnbauer R, Schiller JT et al (1994) Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virology 205:329–335

    Article  CAS  PubMed  Google Scholar 

  • Clifford GM, Gallus S, Herrero R et al (2005) Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366(9490):991–998

    Article  CAS  PubMed  Google Scholar 

  • Daling JR, Weiss NS, Hislop TG et al (1987) Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med 317:973–977

    Article  CAS  PubMed  Google Scholar 

  • Doorbar J (2007) Papillomavirus life cycle organization and biomarker selection. Dis Markers 23(4):297–313

    CAS  PubMed  Google Scholar 

  • Durst M, Gissmann L, Ikenberg H et al (1983) A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 80(12):3812–3815

    Article  CAS  PubMed  Google Scholar 

  • Emeny RT, Wheeler CM, Jansen KU et al (2002) Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J Virol 76(15):7832–7842

    Article  CAS  PubMed  Google Scholar 

  • Evans CA, Gorman LR, Ito Y et al (1962) A vaccination procedure which increases the frequency of regressions of Shope papillomas of rabbits. Nature 193:288–289

    Article  CAS  PubMed  Google Scholar 

  • Favre M, Orth G, Croissant O et al (1975) Human papillomavirus DNA: physical map. Proc Natl Acad Sci USA 72(12):4810–4814

    Article  CAS  PubMed  Google Scholar 

  • Ferguson M, Heath A, Johnes S et al (2006) Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses. Int J Cancer 118(6):1508–1514

    Article  CAS  PubMed  Google Scholar 

  • Fife KH, Wheeler CM, Koutsky LA et al (2004) Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. Vaccine 22(21–22):2943–2952

    Article  CAS  PubMed  Google Scholar 

  • The FUTURE II Study Group (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356(19):1915–1927

    Article  Google Scholar 

  • Galloway DA (1994) Navigating the descent into papillomavirus hell. J Infect Dis 170:1075–1076

    CAS  PubMed  Google Scholar 

  • Gambhira R, Gravitt PE, Bossis I et al (2006) Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Res 66(23):11120–11124

    Article  CAS  PubMed  Google Scholar 

  • Garland SM, Hernandez-Avila M, Wheeler CM et al (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356(19):1928–1943

    Article  Google Scholar 

  • Ghim SJ, Jenson AB, Schlegel R (1992) HPV-1 L1 protein expressed in cos cells displays conformational epitopes found on intact virions. Virology 190(1):548–552

    Article  CAS  PubMed  Google Scholar 

  • Gissmann L, zur Hausen H (1976) Human papilloma virus DNA: physical mapping and genetic heterogeneity. Proc Natl Acad Sci USA 73(4):1310–1313

    Article  CAS  PubMed  Google Scholar 

  • Grimes JL (2006) HPV vaccine development: a case study of prevention and politics. Biochem Mol Biol Educ 34(2):148–154

    Article  CAS  Google Scholar 

  • Harper DM, Franco EL, Wheeler CM et al (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367(9518):1247–1255

    Article  CAS  PubMed  Google Scholar 

  • Hildesheim A, Herrero R, Wacholder S et al (2007) Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA7 298(7):743–753

    Article  CAS  Google Scholar 

  • Inglis S, Shaw A, Koenig S (2006) Chapter 11: HPV vaccines: commercial research & development. Vaccine 24(Suppl 3):S3/99–105

    Google Scholar 

  • Jansen KU, Rosolowsky M, Schultz LD et al (1995) Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 13(16):1509–1514

    Article  CAS  PubMed  Google Scholar 

  • Jarrett WFH, O’Neil BW, Gaukroger JM et al (1990) Studies on vaccination against papillomaviruses: the immunity after infection and vaccination with bovine papillomaviruses of different types. Vet Rec 126:473–475

    CAS  PubMed  Google Scholar 

  • Jewers RJ, Hildebrandt P, Ludlow JW et al (1992) Regions of human papillomavirus type 16 E7 oncoprotein required for immortalization of human keratinocytes. J Virol 66:1329–1335

    CAS  PubMed  Google Scholar 

  • Jochmus-Kudielka I, Schneider A, Braun R et al (1989) Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer. J Natl Cancer Inst 81(22):1698–1704

    Article  CAS  PubMed  Google Scholar 

  • Joura EA, Leodolter S, Hernandez-Avila M et al (2007) Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369(9574):1693–1702

    Article  CAS  PubMed  Google Scholar 

  • Kawana K, Yasugi T, Kanda T et al (2003) Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers. Vaccine 21(27–30):4256–4260

    Article  CAS  PubMed  Google Scholar 

  • Kirnbauer R, Booy F, Cheng N et al (1992) Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 89:12180–12184

    Article  CAS  PubMed  Google Scholar 

  • Kirnbauer R, Taub J, Greenstone H et al (1993) Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 67(12):6929–6936

    CAS  PubMed  Google Scholar 

  • Kmietowicz Z (2008) Opportunity was missed in choice of cervical cancer vaccine, health campaigners say. Br Med J 336:1456–1457

    Article  Google Scholar 

  • Kondo K, Ishii Y, Ochi H et al (2007) Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Virology 358(2):266–272

    Article  CAS  PubMed  Google Scholar 

  • Koshiol JE, Schroeder JC, Jamieson DJ et al (2006) Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus. Int J Cancer 119(7):1623–1629

    Article  CAS  PubMed  Google Scholar 

  • Koutsky L (1997) Epidemiology of genital human papillomavirus infection. Am J Med 102(5A):3–8

    Article  CAS  PubMed  Google Scholar 

  • Koutsky LA, Ault KA, Wheeler CM et al (2002) A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347(21):1645–1651

    Article  CAS  PubMed  Google Scholar 

  • Lorincz AT, Temple GF, Kurman RJ et al (1987) Oncogenic association of specific human papillomavirus types with cervical neoplasia. JNCI 79:671–677

    CAS  PubMed  Google Scholar 

  • Lowy DR, Dvoretzky I, Shober R et al (1980) In vitro tumorigenic transformation by a defined sub-genomic fragment of bovine papilloma virus DNA. Nature 287:72–74

    Article  CAS  PubMed  Google Scholar 

  • Mach H, Volkin DB, Troutman RD et al (2006) Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs). J Pharm Sci 95(10):2195–2206

    Article  CAS  PubMed  Google Scholar 

  • Mitchell H, Drake M, Medley (1986) Prospective evaluation of risk of cervical cancer after cytological evidence of human papilloma virus infection. Lancet 1(8481):573–575

    Article  CAS  PubMed  Google Scholar 

  • Munoz N, Bosch FX (1992) HPV and cervical neoplasia: review of case-control and cohort studies. IARC Sci Publ (119):251–261

    Google Scholar 

  • Orth G, Favre M, Croissant O (1977) Characterization of a new type of human papillomavirus that causes skin warts. J Virol 24(1):108–120

    CAS  PubMed  Google Scholar 

  • Orth G, Favre M, Jablonska S et al (1978) Viral sequences related to a human skin papillomavirus in genital warts. Nature 275(5678):334–336

    Article  CAS  PubMed  Google Scholar 

  • Paavonen J, Jenkins D, Bosch FX et al (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369(9580):2161–2170

    Article  CAS  PubMed  Google Scholar 

  • Parkin DM (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118(12):3030–3044

    Article  CAS  PubMed  Google Scholar 

  • Pass F (1974) Warts. Biology and current therapy. Minn Med 57(10):844–847, 852

    CAS  PubMed  Google Scholar 

  • Pfister H (2003) Chapter 8: human papillomavirus and skin cancer. J Natl Cancer Inst Monogr (31):52–56

    PubMed  Google Scholar 

  • Ramoz N, Rueda LA, Bouadjar B et al (2002) Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet 32(4):579–581

    Article  CAS  PubMed  Google Scholar 

  • Rose RC, Bonnez W, Reichman RC et al (1993) Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol 67(4):1936–1944

    CAS  PubMed  Google Scholar 

  • Rous P (1966) The nobel prize in physiology or medicine 1966. Nobel lecture: the challenge to man of the neoplastic cell. http://nobelprize.org/nobel_prizes/medicine/laureates/1966/rous-lecture.html. Accessed 2 Oct 2008

  • Sasagawa T, Pushko P, Steers G et al (1995) Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology 206:126–135

    Article  CAS  PubMed  Google Scholar 

  • Schäfer F, Florin L, Sapp M (2002) DNA binding of L1 is required for human papillomavirus morphogenesis in vivo. Virology 295(1):172–181

    Article  PubMed  CAS  Google Scholar 

  • Scotto J, Bailar JC III (1969) Rigoni-Stern and medical statistics. A nineteenth-century approach to cancer research. J Hist Med Allied Sci 24(1):65–75

    Article  CAS  PubMed  Google Scholar 

  • Smith MA, Canfell K, Brotherton J et al (2008) The predicted impact of vaccination on human papillomavirus infections in Australia. Int J Cancer 123(8):1854–1863

    Article  CAS  PubMed  Google Scholar 

  • Stanley M (2007) Prophylactic HPV vaccines. J Clin Pathol 60(9):961–965

    Article  PubMed  Google Scholar 

  • Spradbrow PB, Wilson BE, Hoffmann D et al (1977) Immunotherapy of bovine ocular squamous cell carcinomas. Vet Rec 100(18):376–378

    Article  CAS  PubMed  Google Scholar 

  • Suzich JA, Ghim SJ, Palmer-Hill FJ et al (1995) Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 92(25):11553–11557

    Article  CAS  PubMed  Google Scholar 

  • Tsunokawa Y, Takebe N, Kasamatsu T et al (1986) Transforming activity of human papillomavirus type 16 DNA sequence in a cervical cancer. Proc Natl Acad Sci USA 83:2200–2203

    Article  CAS  PubMed  Google Scholar 

  • US Court of Appeals for the Federal Circuit (2007) Ian Frazer and Jian Zhou v. C. Richard Schlegel and A Bennett Jenson, 2006–1154, Interference No. 104, 776. http://www.cafc.uscourts.gov/opinions/06–1154.pdf. Accessed 10 August 2008

  • Villa LL, Costa RL, Petta CA et al (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6(5):271–278

    Article  PubMed  Google Scholar 

  • Watts SL, Phelps WC, Ostrow RS et al (1984) Cellular transformation by human papillomavirus DNA in vitro. Science 225:634–636

    Article  CAS  PubMed  Google Scholar 

  • Yasumoto S, Burkhardt AL, Doniger J et al (1986) Human papillomavirus type 16 DNA-induced malignant transformation of NIH 3T3 cells. J Virol 57:572–577

    CAS  PubMed  Google Scholar 

  • Yuan H, Estes PA, Chen Y et al (2001) Immunization with a pentameric L1 fusion protein protects against papillomavirus infection. J Virol 75(17):7848–7853

    Article  CAS  PubMed  Google Scholar 

  • Zhou J, Sun XY, Stenzel DJ et al (1991) Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185(1):251–257

    Article  CAS  PubMed  Google Scholar 

  • zur Hausen H (1976) Condylomata acuminata and human genital cancer. Cancer Res 36(2 pt 2):794

    CAS  PubMed  Google Scholar 

  • zur Hausen H, Schulte-Holthausen H, Wolf H et al (1974) Attempts to detect virus-specific DNA in human tumors. II. Nucleic acid hybridizations with complementary RNA of human herpes group viruses. Int J Cancer 13(5):657–664

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Diamantina Institute for Cancer Immunology and Metabolic Medicine, The University of Queensland, Princess Alexandra Hospital, Brisbane, Australia

    Ian H. Frazer

Authors
  1. Ian H. Frazer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ian H. Frazer .

Editor information

Editors and Affiliations

  1. Dept. Medicine & Community Health, Brown University, Providence, 02912, U.S.A.

    Andrew W. Artenstein

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Frazer, I.H. (2010). Human Papillomaviruses. In: Artenstein, A. (eds) Vaccines: A Biography. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-1108-7_21

Download citation

Publish with us

Policies and ethics

Search

Navigation